Ligelizumab (INN; development code QGE031) is a humanized IgG1 monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria.
Research funded by Novartis Pharma concluded that Ligelizumab was more effective in treating chronic spontaneous urticaria than omalizumab or placebo.
[8][9][10] In January 2023, a phase three study of ligelizumab in chronic inducible urticaria was terminated after primary endpoints versus omalizumab were not achieved.
[11] In January 2024, a phase three peanut allergy study for ligelizumab was terminated by Novartis.
[13] Immune activation: Dostarlimab Other: Ibalizumab This monoclonal antibody–related article is a stub.